← Back to Clinical Trials
Recruiting NCT06810323

NCT06810323 The ROAM Research Study Therapy (LTOT) Version

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06810323
Status Recruiting
Phase
Sponsor University of Virginia
Condition Pulmonary Disease, Chronic Obstructive
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2025-01-14
Primary Completion 2028-12

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2025-01-14 with a primary completion date of 2028-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this research is to test a device being developed that can see how patients use oxygen therapy over a long period of time. This study will focus on developing a new display part called ROAM module which will be attached to your oxygen source. The display will provide easily-accessible information that can show how you interact with your supplies and the oxygen machine automatically without connecting the oxygen source to the internet or other devices.

Eligibility Criteria

Inclusion Criteria: Post-Bronchodilator FEV1/FVC \<.80 * Race demographics of the recruitment area reflect the population of the Charlottesville Metropolitan Statistical Area (MSA). * Due to underrepresentation in local demographics, special effort (via targeted advertising) will be made to recruit Hispanic participants to better match national percentages. * Participants with medical history of COPD * Subjects has to have a prescription for oxygen use via nasal cannula or mask at home * At baseline of health with no hospitalization/exacerbation within the past 6 weeks * Use of Continuous oxygen at baseline Exclusion Criteria: Post -Bronchodilator FEV1 \< 25% * Intermittent oxygen use at home * Inability to understand simple instructions * No respiratory infections and exacerbation within 6 weeks of study

Contact & Investigator

Central Contact

Roselove NUNOO-ASARE, MA

✉ RNN3B@VIRGINIA.EDU

📞 434-243-6074

Principal Investigator

Yun M Shim, MD

PRINCIPAL INVESTIGATOR

Division of Pulmonary and Critical Medicine

Frequently Asked Questions

Who can join the NCT06810323 clinical trial?

This trial is open to participants of all sexes, studying Pulmonary Disease, Chronic Obstructive. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06810323 currently recruiting?

Yes, NCT06810323 is actively recruiting participants. Contact the research team at RNN3B@VIRGINIA.EDU for enrollment information.

Where is the NCT06810323 trial being conducted?

This trial is being conducted at Charlottesville, United States.

Who is sponsoring the NCT06810323 clinical trial?

NCT06810323 is sponsored by University of Virginia. The principal investigator is Yun M Shim, MD at Division of Pulmonary and Critical Medicine. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology